Navigation Links
Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens
Date:9/16/2008

DOYLESTOWN, Pa., Sept. 16 /PRNewswire-FirstCall/ -- The Quigley Corporation (Nasdaq: QGLY), http://www.quigleyco.com, announced positive results from a follow up study conducted by its wholly owned subsidiary, Quigley Pharma, http://www.QuigleyPharma.com, designed to examine the ability of its veterinary anti-viral compound QR448(a) to prevent the transmission of Infectious Bronchitis Virus (IBV) from infected to non-infected 2 week old commercial broiler chickens, a consumer meat type bird. After the 14 day study only 4% of the birds treated with QR448(a) contracted IBV from previously infected birds versus 22% of birds that contracted IBV from previously infected birds and were not treated with QR448(a). This data shows that treating these birds with QR448(a) produced a statistically significant 5.5 fold decrease in the transmission of IBV compared to birds that were not treated with the QR448(a) compound.

Veterinary poultry products industry experts and those familiar with prevention and control of IBV recognize that abating transmission is perhaps one of the most important ways to economically prevent, control and manage potential losses due to IBV outbreaks.

The Company recently announced positive results of a study to determine the duration of anti-viral effect of QR448(a) against IBV in commercial broiler chickens, which indicated that 1 day old commercial broilers, when treated with QR448(a) were protected 50-100% of the time from the clinical pathogenic effects of IBV for up to 4 days compared to 0-20% of the time in un-treated birds.

The Company plans to continue to build on these recent positive results to improve its potential commercial and partnering prospects.

Dr. Richard Rosenbloom Executive VP and COO of Quigley Pharma stated: "In addition to observing the positive effects of preventing transmission of a particularly challenging viral isolate, these results have also demonstrated that the QR448(a) compound can effectively be applied to a larger population of birds and in an environment that closely resembles a commercial scale."

Dr. Mark Jackwood Professor, Department of Population Health, College of Veterinary Medicine, University of Georgia, who conducted the study, stated: "By demonstrating the ability of QR448(a) to significantly decrease transmission of Arkansas vaccine virus, this experiment directly addresses an extremely important problem of persistence of this isolate in commercial broiler flocks and the potential for managing a real industry problem by limiting persistence and reducing outbreaks. This work also shows that QR448(a) is effective against a different IBV serotype, indicating that it has the potential to control all infectious bronchitis viruses regardless of virus type. In addition, spray treatment of QR448(a) is fast, extremely easy, and suitable for mass delivery of the compound to thousands of commercial birds."

About the Study:

-- Two colonies of 120 two week old commercial broiler chickens were housed

in 8' X 8' colony houses. Twenty birds from each colony were

identified and infected with a full dose of the commercially available

Arkansas type IBV vaccine virus and isolated for 2 hours. Due to

safety, exposure and handling concerns of IBV in a large scale

experiment, Arkansas type vaccine virus was recognized as a comparable

surrogate for this investigation. The infected birds were reintroduced

to their colony after which time one colony of birds were spray treated

with 1ml of a 1:20 dilution of QR448(a) and the other colony was not

spray treated.

-- At 3, 7, 10 and 14 days post treatment, 25 non-infected and 5 infected

birds were removed and their tracheas swabbed and tested for the

detection and transmission of virus from infected to non-infected birds.

-- It was demonstrated clearly that the QR448(a) treated colony showed a

statistically significant 5.5 fold reduction in transmission of virus at

14 days post-exposure [(P value, less than and/or equal to 0.1) One way

analysis of variance, Student's test] and a non-statistical 3 fold

reduction was observed at 10days post-exposure compared to the colony

that was not treated with QR448(a).

-- Serology, necropsy and clinical observations confirmed that other avian

pathogens and or immune-suppression had not influenced the results and

were consistent with exposure to a non-pathogenic vaccine virus.

-- Since QR448(a) has been shown previously to be effective against

pathogenic isolates of IBV and now against Arkansas vaccine virus, it is

expected that it will also limit transmission of pathogenic IBV in

broilers and thereby decrease the severity of the disease.

The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will issue an investigational new animal drug number or allow this compound to be marketed for IBV. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities and Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

CONTACT: Media Investor Relations

Karen Pineman Carl Hymans

G.S. Schwartz & Co. G.S. Schwartz & Co.

212.725.4500 212.725.4500

kpineman@schwartz.com carlh@schwartz.com


'/>"/>
SOURCE Quigley Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
2. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Promising Cystic Fibrosis Compound on Track for Development
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
8. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
9. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
10. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
11. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Australia,s successful biotechnology scientists, Dr Graham ... Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is seeking ... ASX. Noxopharm is a clinic-ready company with its first ... study later this year. NOX66 ... cancer patients - the ability of cancers to become resistant to ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
Breaking Medicine News(10 mins):